scholarly journals Formulation And Characterization of Carageenan Gels Encapsulating Amphotericin B And Lactobacillus acidophilus Against Candidal Vaginitis

2017 ◽  
Vol 4 (1) ◽  
pp. 37-49
Author(s):  
R Kaur ◽  
M Khurana ◽  
M Bindal ◽  
A Sharma
Keyword(s):  
Candida Albicans ◽  
Drug Release ◽  
Sustained Release ◽  
Amphotericin B ◽  
Lactobacillus Acidophilus ◽  
Drug Carriers ◽  
In Vitro Drug Release ◽  
Antimicrobial Studies

The present study is concerned with the development and characterization of bioadhesive carageenan gel encapsulating Amphotericin B and Lactobacillus acidophillus, prepared by graft co-polymeriztion against Candidal vaginitis. Intravaginal gel systems based on bioadhesive polymer (carrageenan) were characterized with respect to swelling index, bioadhesive strength, percent encapsulation and in vitro drug release antimicrobial studies. A marked increase in swelling index of gel encapsulating Lactobacillus was found to be 1.9±0.35. The percent encapsulation of drug was found to be 98.63%±.0.2% and that of Lactobacillus was 91.81 ±0.01. The viability was observed for interval of 6 hrs on trypton soya agar and showed that viability was highly conserved till 4 hrs. The antimicrobial study of gels encapsulating Amphotericin B and Lactobacillus showed that carageenan gel can inhibit Candida albicans upto a maximum extent. Bioadhesivity study also conducted for gels that showed a bioadhesivity of 84.66% ±.0.5% with drug, 88.66% ±.02% with Lactobacillus. In-vitro drug release showed a sustained type release of drug from the polymer i.e. there was initial burst of Amphotericin B up to 5 hours, after which there was a sustained release upto 10 days. Thus it has been concluded from the present study that bioadhesive gels encapsulating Amphotericin B can act as promising drug carriers along with Lactobacillus against candidal vaginitis.

scholarly journals Preparation and characterization of amphotericin B mannosylated liposomes for effective management of visceral leishmaniasis

2021 ◽  
Vol 11 (5-S) ◽  
pp. 113-118
Author(s):  
Anuradha Soni ◽  
Vivek Jain ◽  
Sunil Kumar Jain ◽  
Pushpendra Kumar Khangar
Keyword(s):  
Visceral Leishmaniasis ◽  
Drug Release ◽  
Zeta Potential ◽  
Amphotericin B ◽  
In Vitro Drug Release ◽  
Multilamellar Liposomes ◽  
Film Method ◽  
Mannosylated Liposomes

Visceral leishmaniasis (VL) is a chronic debilitating disease prevalent in tropical and subtropical regions, caused by protozoan parasites of the genus Leishmania. Annually, it is approximated the occurrence of 0.2 to 0.4 million novel cases of the disease worldwide. The cast film method was used to prepared cationic and mannosylated liposomes. The surface of the Amphotericin B (Amp B)-bearing cationic multilamellar liposomes was covalently coupled with p-aminophenyl-α-D-mannoside using glutaraldehyde as a coupling agent, which was proved by agglutination of the vesicles with concanavalin A. The prepared liposomes were characterized for shape, size, % drug entrapment, vesicle count, zeta potential and in vitro drug release. Vesicle sizes of cationic and mannosylated liposomes were establish to be 2.71±0.12and 1.62±0.08μm, respectively. Zeta potential of cationic liposomes was higher (28.38 ± 0.3 mV), as compared to mannosylated liposomes (15.7 ± 0.8 mV). % drug release from cationic and mannose-coupled liposomes was established to be 45.7% and 41.9%, respectively, after 24 hrs. In the present work, cationic and mannosylated liposomes of Amp B were prepared, optimized and characterized for effectual organization of VL. Keywords: Mannosylated liposomes, Amphotericin B, Leishmaniasis, % drug release.

scholarly journals FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF LEVOSULPIRIDE BY USING NATURAL POLYMER

2017 ◽  
Vol 10 (5) ◽  
pp. 285
Author(s):  
S Shanmugam
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Xanthan Gum ◽  
Diffusion Mechanism ◽  
Matrix Tablets ◽  
In Vitro Dissolution ◽  
Release Kinetic ◽  
Natural Polymers ◽  
In Vitro Drug Release

Objective: The objective of the present study was to develop sustained release matrix tablets of levosulpiride by using natural polymers.Method: The tablets were prepared with different ratios of Chitosan, Xanthan gum and Guar gum by wet granulation technique. The solubility study of the levosulpiride was conducted to select a suitable dissolution media for in vitro drug release studies.Results: Fourier transform infrared (FTIR) study revealed no considerable changes in IR peak of levosulpiride and hence no interaction between drug and the excipients. DSC thermograms showed that no drug interaction occurred during the manufacturing process. In vitro dissolution study was carried out for all the formulation and the results compared with marketed sustained release tablet. The drug release from matrix tablets was found to decrease with increase in polymer ratio of Chitosan, Xanthan gum and Guar gum.Conclusion: Formulation LF3 exhibited almost similar drug release profile in dissolution media as that of marketed tablets. From the results of dissolution data fitted to various drug release kinetic equations, it was observed that highest correlation was found for First order, Higuchi’s and Korsmeyer equation, which indicate that the drug release occurred via diffusion mechanism.  Keywords: Levosulpiride, sustained release tablets, natural polymers, in vitro drug release studies 

scholarly journals Formulation development and characterization of fast disintegrating tablets of Nimesulide

2012 ◽  
Vol 4 (2) ◽  
pp. 25-28
Author(s):  
Manoj M Nitalikar ◽  
Dinesh M Sakarkar
Keyword(s):  
Drug Release ◽  
Critical Concentration ◽  
Formulation Development ◽  
Compression Method ◽  
In Vitro Drug Release ◽  
Sodium Starch Glycolate ◽  
Evaluation Parameters ◽  
Fast Disintegrating Tablets

An attempt was made to prepare fast dissolving tablets of anti-inflammatory drug Nimesulide preparing by direct compression method. The superdisintegrants Cross-carmellose and Sodium starch glycolate were used in different concentrations. Twelve formulations using those superdisintegrants at different concentration levels were prepared to access their efficiency and critical concentration level. Different evaluation parameters for tablet were studied. Tablets containing Cross-carmellose showed superior organoleptic properties and excellent in-vitro drug release as compared to other formulations. It was observed that on increasing the concentration of Cross-carmellose, the rate of disintegration was increased whereas on increasing the concentration of Sodium starch glycolate the rate of disintegration was decreased. The percentage drug release was observed as 96.32% when the concentration of Cross-carmellose was increased, whereas the same was not observed on increasing the concentration of Sodium starch glycolate. DOI: http://dx.doi.org/10.3329/sjps.v4i2.10436 S. J. Pharm. Sci. 4(2) 2011: 25-28

Development of Nateglinide Loaded Graphene Oxide-Chitosan Nanocomposites: Optimization by Box Behnken Design

2019 ◽  
Vol 11 (2) ◽  
pp. 142-153
Author(s):  
Rutuja V. Deshmukh ◽  
Pavan Paraskar ◽  
S. Mishra ◽  
Jitendra Naik
Keyword(s):  
Fourier Transform ◽  
Graphene Oxide ◽  
Electron Microscope ◽  
Drug Release ◽  
Sustained Release ◽  
Encapsulation Efficiency ◽  
In Vitro Drug Release ◽  
Box Behnken Design ◽  
X Ray

Background: Nateglinide is an antidiabetic drug having biological half-life 1.5 h which shows a concise effect. Graphene oxide along with chitosan can be used as a nanocarrier for sustained release of Nateglinide. Objective: To develop Nateglinide loaded graphene oxide-chitosan nanocomposites and to evaluate for different characterization studies. Methods: Graphene Oxide (GO) was synthesized by improved hummer’s method and drug-loaded Graphene oxide - chitosan nanocomposites were prepared. Box Behnken design was used to carry out experiments. The nanocomposites were characterized for encapsulation efficiency and drug release. Morphology was studied using field emission scanning electron microscope and transmission electron microscope. An interaction between drug, polymer and GO was investigated by Fourier transform infrared spectroscopy and X-ray diffractometer along with in vitro drug release study. Results: The statistical evaluation of the design showed linear and quadratic models which are significant models for encapsulation efficiency (R1 0.6883, 0.9473) and drug loading (R2 0.6785, 0.9336), respectively. Fourier transform infrared spectroscopy showed the compatibility of GO, Chitosan and Nateglinide. X-ray diffractometer reveals the change in degree of crystallinity of drug. FE-SEM and TEM images confirmed the distribution of the drug within the nanocomposites. Design expert reveals that the concentration of GO has great influence on encapsulation efficiency. In Vitro drug release showed the sustained release of drug over the period of 12 h. Conclusion: GO-Chitosan nanocomposites can be used as a sustained release carrier system for Nateglinide to reduce dose frequency of drug as well as its probable side effects.

scholarly journals Preparation iiand characterization of mucoadhesive microcapsules of paclitaxel

2020 ◽  
Vol 11 (2) ◽  
pp. 2575-2583
Author(s):  
Chinmaya Mahapatra ◽  
Padala Narasimha Murthy ◽  
Sudhir Kumar Sahoo ◽  
Anjan Kumar Mahapatra ◽  
Prasanna Kumar Dixit
Keyword(s):  
Drug Release ◽  
Morphological Characters ◽  
Swelling Ratio ◽  
Particle Size Range ◽  
In Vitro Drug Release ◽  
Mucoadhesive Polymer ◽  
Alginate Concentration ◽  
And Control

The objective of the present work was to develop paclitaxel encapsulated mucoadhesive microcapsules with an aim to enhance its efficacy and control the drug release in cancer patients. Paclitaxel microcapsules with a coat consisting of sodium alginate and mucoadhesive polymer such as acacia, Carbomer 941, Povidone K-30, Macrogol (PEG 6000) were prepared by ionotropic gelation technique and were evaluated for morphological characters, drug content, loading efficiency, drug–polymer interactions, swelling ratio, mucoadhesive properties and in vitro drug release. The resulting microcapsules were discrete, spherical, and free-flowing with a particle size range of 534 to 822 µm. The microencapsulation efficiency was 45.09–99.83%. The microcapsules prepared with alginate along with macrogol (F4M) have exhibited good mucoadhesive property in the in vitro wash off test. The swelling ratio of microcapsules was enhanced with increased alginate concentration and the formulation (F4) showed highest swelling index of 2666. Paclitaxel release from these mucoadhesive microcapsules was slow and extended over a period of 6 h and further depends upon the concentration of the alginate. The percent drug release of alginate-acacia microcapsules (F4Ac) was higher than other formulations in the present study. In conclusion, alginate-acacia mucoadhesive microcapsules could be promising vehicle for oral controlled release of paclitaxel.

scholarly journals Formulation and Evaluation of Meloxicam In-Situ Gel Designed for Sustained Drug Release to Reduce Dosing Frequency in the Management of Arthritis

2021 ◽  
Vol 69 (2) ◽  
Author(s):  
Meesala. Srinivasa Rao ◽  
M. S Chandra Goud ◽  
C. V. Reddy
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Sustained Drug Release ◽  
In Vitro Drug Release ◽  
In Situ Gel ◽  
Dosing Frequency ◽  
Gel Formulations

Meloxicam has short biological half-life and is rapidly eliminated, frequent oral administration is necessary to maintain its therapeutic concentration, but this can increase chances of missing dose. This makes Meloxicam a good applicant for oral sustained release formulation. The objective of study was to develop in-situ gel formulations of Meloxicam for sustained release to reduce the dosing frequency in the treatment of rheumatoid arthritis. Method of Ion sensitive in-situ gelation was used in this study. Meloxicam In-situ gel formulations were prepared by varying concentrations of sodium alginate as a bio-degradable gel forming polymer, CaCl2 as a cross-linking agent and Chitosan/ HPMCK4/HPMCK15/Guar gum/Gellan gum/ Xantha gum/pectin were used as drug release rate controlling polymers. The formulations F11-F18 were assessed for Physical appearance, pH, in-vitro drug release, viscosity, in-vitro gelling capacity and drug content. FTIR, DSC and in-vivo drug kinetics studies was conducted for Meloxicam, excipients used and optimized formulation. Formulations showed an optimum viscosity that will allow ease of administration and swallowing. All formulations are shown pH between4.7-4.9, floating lag time was 2-3sec and floated for >12 hrs. In vitro drug release studies reporting that commercially available product Meloxicam SR has showed 99.92% drug release in 8 hrs and out of eight formulations F11 showing in-vitro drug release of 99.52% over a 12hrs extended period. FTIR studies revealed no interaction between drug and excipients used. The results of In-vivo kinetic studies are approving the better performance of the optimized formulation in comparison to marketed formulation, The Cmax, Tmax, half-life AUC values are confirming the same thing. In conclusion, Formulation (F11) was selected as optimized formulations could be offered as shows optimum sustained drug release compared to commercial formulation. Hence Meloxicam containing Chitosan as drug release controll

Design, development and characterization of ketorolac tromethamine polymeric nanosuspension

2019 ◽  
Vol 10 (9) ◽  
pp. 585-597 ◽  
Author(s):  
Pankaj A Jadhav ◽  
Adhikrao V Yadav
Keyword(s):  
Drug Release ◽  
Entrapment Efficiency ◽  
Slight Reduction ◽  
Ketorolac Tromethamine ◽  
Design Development ◽  
In Vitro Drug Release ◽  
Sustained Effect ◽  
Eudragit Rl

Aim: At present, various ophthalmic formulations show low bioavailability. The rationale of present work was to design and develop stable ketorolac tromethamine nanosuspension with sustained effect and greater permeability for ocular drug delivery and increased ocular residence. Materials & methods: Formulations were designed by using central composite design, developed by combined nanoprecipitation and probe sonication method. Results & discussion: Nanosuspensions depicted the size range of the particles in between 199 and 441 nm with slight reduction in crystallinity of drug. In vitro drug release revealed that higher % entrapment efficiency of drug in nanosuspension delays the drug release. Conclusion: Eudragit RL-100-based nanosuspension increases viscosity and avoids problems like drug loss from precorneal surface and rapid drainage through nasolacrimal areas.

Sign in / Sign up

Export Citation Format

Share Document